Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENTYVIO Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study

X
Trial Profile

ENTYVIO Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms EVOLVE; EVOLVE Expansion study
  • Sponsors Takeda
  • Most Recent Events

    • 10 May 2023 Primary endpoint (Cumulative Rates of Clinical Remission Over 36 Months Compared Between VDZ and UST Cohorts) has not been met.
    • 10 May 2023 According to a Takeda media release, the data from this study was presented as an oral presentation at Digestive Disease Week (DDW) 2023 in Chicago, IL.
    • 10 May 2023 Results assessing efficacy and safety presented in a Takeda media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top